Today: 20 March 2026
Subscribe
Browse Category

Pharmaceutical Industry 5 December 2025 - 15 December 2025

Pfizer Stock (PFE) News Today: Dividend, 2026 Guidance Call, Obesity Deals, and Analyst Forecasts (Dec. 15, 2025)

Pfizer Stock (PFE) News Today: Dividend, 2026 Guidance Call, Obesity Deals, and Analyst Forecasts (Dec. 15, 2025)

Pfizer shares traded at $25.85 as of 12:08 UTC Monday, unchanged from Friday’s close. The company will hold a conference call Tuesday morning to provide full-year 2026 financial guidance. Pfizer’s board declared a $0.43 first-quarter 2026 dividend, marking its 349th consecutive quarterly payout. Market cap stands near $147 billion.
15 December 2025
····
Milestone Pharmaceuticals (MIST) Stock: FDA Approval of CARDAMYST, Launch Timeline, and Analyst Forecasts (Dec. 15, 2025)

Milestone Pharmaceuticals (MIST) Stock: FDA Approval of CARDAMYST, Launch Timeline, and Analyst Forecasts (Dec. 15, 2025)

The FDA approved Milestone Pharmaceuticals’ CARDAMYST (etripamil) nasal spray for adults with paroxysmal supraventricular tachycardia, marking the first new U.S. PSVT treatment in over 30 years. The company targets retail availability in Q1 2026. Shares showed sharp volatility after the announcement. Milestone scheduled an investor call for December 15 to discuss launch plans.
15 December 2025
·
CSL Limited Stock (ASX:CSL) Update: Hemgenix 5-Year Data, Vaccine Audit Fallout, Buyback Support — Week Ahead Outlook (Updated 14 Dec 2025)

CSL Limited Stock (ASX:CSL) Update: Hemgenix 5-Year Data, Vaccine Audit Fallout, Buyback Support — Week Ahead Outlook (Updated 14 Dec 2025)

CSL shares closed Friday at A$183.93, up 2.86% on the day but down 0.85% for the week. The company reported five-year data for its hemophilia B gene therapy HEMGENIX, showing 94% of patients remained free from continuous treatment. Investors also weighed scrutiny of CSL Seqirus vaccine deals and the ongoing A$750 million buyback.
14 December 2025
··
Anavex Life Sciences (AVXL) Stock Drops After EMA Recommends Refusal of Blarcamesine: Latest News, Analyst Forecasts, and What’s Next (Dec. 12, 2025)

Anavex Life Sciences (AVXL) Stock Drops After EMA Recommends Refusal of Blarcamesine: Latest News, Analyst Forecasts, and What’s Next (Dec. 12, 2025)

European regulators on Dec. 12 recommended refusing marketing authorization for Anavex’s Alzheimer’s drug Blarcamesine, citing insufficient evidence of effectiveness, unresolved safety issues, and quality concerns. The EMA said Anavex may request re-examination within 15 days. Anavex shares, already volatile, moved sharply in early trading.
12 December 2025
·
GSK Stock News Today (Dec. 12, 2025): Arexvy EU Expansion, Blujepa FDA Approval, Analyst Forecasts and What’s Next

GSK Stock News Today (Dec. 12, 2025): Arexvy EU Expansion, Blujepa FDA Approval, Analyst Forecasts and What’s Next

GSK shares traded near $48.88 Friday as the company reported key regulatory wins. The EMA’s CHMP backed expanding Arexvy’s RSV vaccine to all adults 18+ in Europe, with a final decision expected in February. The FDA also approved Blujepa (gepotidacin) for gonorrhea, marking the first new antibiotic class for the infection in decades. Analyst consensus sees Arexvy sales rising to £1.17 billion by 2031.
12 December 2025
··
Pfizer (PFE) Stock Outlook After the November 21 FDA Win: Obesity Deals, Cost Cuts and a 6.7% Dividend Yield

Pfizer (PFE) Stock Outlook After the November 21 FDA Win: Obesity Deals, Cost Cuts and a 6.7% Dividend Yield

Pfizer shares traded at $25.66 on December 11, 2025, following an FDA approval for PADCEV plus Keytruda in bladder cancer and a new GLP‑1 weight-loss deal. The company declared a $0.43 per-share dividend for Q4, marking its 348th consecutive quarterly payout. Pfizer’s annualized yield stands at about 6.7%. Consensus 2025 EPS is $3.1–$3.2, giving a forward P/E near 8.
11 December 2025
·
Wave Life Sciences (WVE) Stock on December 11, 2025: Obesity Breakthrough, 180% Rally, $350M Offering and Fresh Analyst Targets

Wave Life Sciences (WVE) Stock on December 11, 2025: Obesity Breakthrough, 180% Rally, $350M Offering and Fresh Analyst Targets

Wave Life Sciences shares surged over 180% in a week after Phase 1 data showed its obesity drug WVE-007 reduced visceral fat by up to 10% and increased lean mass. The stock hit a five-year high near $22 before retreating to $17.06 following a $350 million equity offering and insider selling. Analyst price targets jumped, but Wave remains unprofitable with high valuation risk.
11 December 2025
···
Vera Therapeutics (VERA) Stock Outlook: December 11, 2025 Update on Public Offering, Atacicept BLA and Wall Street Targets

Vera Therapeutics (VERA) Stock Outlook: December 11, 2025 Update on Public Offering, Atacicept BLA and Wall Street Targets

Vera Therapeutics shares traded near $46 on December 11, 2025, after announcing a $261 million stock offering at $42.50 per share. The company filed a Biologics License Application for atacicept in IgA nephropathy and reported strong late-stage clinical results. Shares are up nearly 100% in six months, with market cap around $2.9–3.0 billion. The offering is expected to close today.
11 December 2025
·
Arrowhead Pharmaceuticals (ARWR) Stock Near 52‑Week High After FDA Approval and New Alzheimer’s Trial: Latest News & Forecasts as of December 11, 2025

Arrowhead Pharmaceuticals (ARWR) Stock Near 52‑Week High After FDA Approval and New Alzheimer’s Trial: Latest News & Forecasts as of December 11, 2025

Arrowhead Pharmaceuticals shares surged to a new 52-week high above $72 on December 11 after the FDA approved its first drug, Redemplo, for familial chylomicronemia syndrome. The stock has climbed from the low-$40s to around $70 in a month, pushing market value to $9.6 billion, up over 300% year-over-year. The company also received an FDA Breakthrough Therapy designation and launched its first Alzheimer’s trial.
11 December 2025
··
Pfizer (PFE) Stock After Hours on December 9, 2025: Obesity Pill Deal, RSV Questions, and What to Watch Before the Opening Bell

Pfizer (PFE) Stock After Hours on December 9, 2025: Obesity Pill Deal, RSV Questions, and What to Watch Before the Opening Bell

Pfizer shares closed down 1.7% at $25.33 on December 9, 2025, with volume below average. After hours, the stock edged up to $25.40 as investors reacted to Pfizer’s new global licensing deal with YaoPharma for an early-stage oral obesity drug. The agreement includes a $150 million upfront payment and potential milestones up to $2.1 billion.
10 December 2025
····
Eli Lilly Stock (LLY) on December 9, 2025: Price, Alabama Megaplant, Jaypirca Breakthrough and 2026–2030 Forecasts

Eli Lilly Stock (LLY) on December 9, 2025: Price, Alabama Megaplant, Jaypirca Breakthrough and 2026–2030 Forecasts

Eli Lilly shares traded near $980 Tuesday, down 1.6% but up 57% from their 52-week low, with a market cap around $880 billion after briefly topping $1 trillion in November. The company announced a $6 billion manufacturing facility in Alabama, reported strong Q3 earnings, raised guidance, and posted an 80% risk reduction in a key leukemia trial. Lilly also closed its Adverum acquisition and raised its dividend.
9 December 2025
·
Therapeutics (KYMR) Stock Rockets on KT‑621 Eczema Breakthrough, Then Pauses After $500M Share Offering – 9 December 2025 Update

Therapeutics (KYMR) Stock Rockets on KT‑621 Eczema Breakthrough, Then Pauses After $500M Share Offering – 9 December 2025 Update

Kymera Therapeutics shares jumped 41.6% to close at $94.30 on December 8 after its oral STAT6 degrader KT-621 showed dupilumab-like efficacy and clean safety in a small Phase 1b eczema trial. The company announced a $500 million stock offering the same day, sending shares lower in after-hours trading. Analyst price targets rose, some reaching $138.
9 December 2025
····
Structure Therapeutics (GPCR) Stock Explodes on Obesity Pill Breakthrough: Latest News, Analyst Targets and 2026–2035 Outlook

Structure Therapeutics (GPCR) Stock Explodes on Obesity Pill Breakthrough: Latest News, Analyst Targets and 2026–2035 Outlook

Structure Therapeutics shares doubled to $69.98 mid-day December 9 after reporting strong Phase 2b data for its oral obesity drug, aleniglipron. The 120 mg dose showed 11.3% placebo-adjusted weight loss over 36 weeks; higher doses reached 15.3%. No drug-induced liver injury or QTc prolongation was reported. Market cap stands near $4 billion, with the stock trading close to its 52-week high.
9 December 2025
··
Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough and $250M Equity Offering

Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough and $250M Equity Offering

Wave Life Sciences shares surged 147% to $18.52 after reporting positive Phase 1 data for its RNA obesity drug WVE-007 on December 8, raising its market cap to $3 billion. The company launched a $250 million equity offering following the rally. Interim results showed a 9.4% reduction in visceral fat and a 3.2% gain in lean mass after one dose, outperforming GLP-1 drugs in early comparisons.
9 December 2025
···
Kymera Therapeutics (KYMR) Stock Soars on KT‑621 Eczema Data: What December 8, 2025 Means for Investors

Kymera Therapeutics (KYMR) Stock Soars on KT‑621 Eczema Data: What December 8, 2025 Means for Investors

Kymera Therapeutics shares jumped nearly 50% Monday, closing near $96 after hitting an intraday high above $100, following strong Phase 1b results for its oral STAT6 degrader KT‑621 in atopic dermatitis. The trial showed about 98% median STAT6 degradation in blood and 94% in skin lesions. Trading volume was far above normal. Stifel raised its price target as the stock marked a new 52-week high.
8 December 2025
··
Structure Therapeutics (GPCR) Stock Soars on Obesity Pill Data: Latest News, Analyst Forecasts and 2026 Outlook (December 8, 2025)

Structure Therapeutics (GPCR) Stock Soars on Obesity Pill Data: Latest News, Analyst Forecasts and 2026 Outlook (December 8, 2025)

Structure Therapeutics shares surged 101% to $69.46 on December 8 after reporting positive Phase 2b data for aleniglipron, its oral GLP-1 agonist for obesity. Patients on 120 mg lost 12.1% of body weight at 36 weeks versus 0.8% for placebo. The company held $799 million in cash as of September 30.
8 December 2025
···
Pfizer (PFE) Stock on December 6, 2025: Metsera Deal, 2025 Guidance and What Wall Street Expects Next

Pfizer (PFE) Stock on December 6, 2025: Metsera Deal, 2025 Guidance and What Wall Street Expects Next

Pfizer shares closed at $26.03 on December 5, 2025, up 1.28% and 24% above April’s low. The stock yields about 6.6% with an annualized dividend of $1.72 per share and has paid 347 consecutive quarterly dividends. Pfizer’s Q3 revenue fell 6% to $16.65 billion, but adjusted EPS beat expectations at $0.87. The stock trades at 8–9x forward earnings, below the market average.
6 December 2025
···
Praxis Precision Medicines (PRAX) Soars on FDA Momentum and Epilepsy Breakthroughs as Stock Hits New High on December 5, 2025

Praxis Precision Medicines (PRAX) Soars on FDA Momentum and Epilepsy Breakthroughs as Stock Hits New High on December 5, 2025

Praxis Precision Medicines shares jumped nearly 40% intraday on December 5 after its pivotal epilepsy trial was stopped early for efficacy and the company reported a positive pre-NDA meeting with the FDA for its essential tremor drug. By late morning, PRAX traded around $265–266, hitting a new 52-week high and pushing its market cap above $1.1 billion. The stock is up over 200% year-to-date.
5 December 2025
·
1 … 4 5 6 7 8

Stock Market Today

  • Kosmos Energy (KOS) Faces Valuation Debate After 200% Surge Over Three Months
    March 20, 2026, 5:00 AM EDT. Kosmos Energy (KOS) has surged nearly 200% in 90 days, prompting investor reassessment of its valuation. The stock closed at $2.98, above a commonly cited fair value of $2.51, implying it may be overvalued based on long-term production and LNG exposure assumptions. Yet, an alternate discounted cash flow (DCF) model suggests a far higher fair value of $11.44, highlighting a 74% discount at current prices. Cost-cutting and LNG growth underpin optimism, but risks include impairments and refinancing challenges. The differing signals illuminate ongoing debate around Kosmos's growth prospects and risk profile amid a volatile energy market.
Go toTop